SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule Of Revenue Sources Health Care Organization Table Text Block

Net service revenue by payor class as a percentage of total net service revenue for each of our operating segments as described in Note 8 - Segment Information is as follows:

	For the Three-Month Periods Ended March 31,
	2024		2023
Home Health:
Medicare	38	%	39	%
Non-Medicare - Episodic-based	8	%	7	%
Non-Medicare - Non-episodic based	18	%	15	%
Hospice:
Medicare	33	%	33	%
Non-Medicare	2	%	2	%
Personal Care (1)	—	%	3	%
High Acuity Care	1	%	1	%
	100	%	100	%

(1) We divested our personal care business on March 31, 2023.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):

	As of March 31, 2024		As of December 31, 2023
Cash and cash equivalents	$	108.2	$	126.5
Restricted cash	12.5		12.4
Cash, cash equivalents and restricted cash	$	120.7	$	138.9

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of March 31, 2024		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
$450 million Term Loan	$	366.3	$	—	$	361.6	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

	For the Three-Month Periods Ended March 31,
	2024	2023
Weighted average number of shares outstanding - basic	32,670	32,558
Effect of dilutive securities:
Stock options	10	13
Non-vested stock and stock units	299	72
Weighted average number of shares outstanding - diluted	32,979	32,643
Anti-dilutive securities	388	323